Meta-Analysis and Clinical Guidance of Oxygenated Hypothermic Machine Perfusion for Kidney Transplantation
In the first meta-analysis examining the role of HMPO2 in kidney transplantation finds it may lower adverse events, particularly in DCD cases.
Highlights
- HMPO2 reduced the number of patients with adverse events and the proportion of severe adverse events.
- HMPO2 performed better in donation after cardiac death, and continuous
- HMPO2 was superior to end-HMPO2.
Background
It remains unclear whether oxygenated hypothermic machine perfusion (HMPO2) during kidney preservation is beneficial for prognosis.
Methods
A comprehensive search of databases and clinical trial registries was conducted to identify eligible studies on HMPO2 application during kidney transplantation. A multi-subgroup analysis was further conducted to explore the heterogeneity among studies.
Results
Compared to the control treatment, HMPO2 did not significantly alter the incidence of postoperative acute rejection, graft survival, patient mortality, delayed graft function (DGF), functional DGF, primary nonfunction, or estimated glomerular filtration rate, whereas the warm ischemia time appeared to be longer. However, the number of patients with adverse events and the proportion of severe adverse events were reduced in the HMPO2 group. Subgroup analysis indicated that HMPO2 performed better in donation after cardiac death (DCD), and continuous HMPO2 was superior to end-HMPO2.